Fig. 3From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatmentAcute and long-term toxicity assessment by blood analysis. CD-1 normal mice received 0.74 MBq (20 µCi) 212Pb-TCMC-YS5 (study group) or no treatment (control group). A Hematology analysis of mice 14 days and 90 days post-treatment. B Blood clinical chemistry analysis of mice 14 days and 90 days post-treatmentBack to article page